The House Committee on Oversight and Accountability met last week for a hearing on the Inflation Reduction Act's first year. As one of the witnesses pointed out, the law's implementation — particularly its drug pricing reforms — have already run afoul of some of our government's most basic norms of transparency and accountability.
Normally, federal officials would give citizens a chance to voice concerns about a policy shift of this magnitude — and would need to address that feedback in the final policy. But the IRA's drug pricing provisions sidestep this process altogether by requiring the rule be implemented by "program instruction or other forms of program guidance" — a sub-regulatory process in which the public gets little say.
America's relatively free market in prescription drugs has been an engine of medical progress for decades. It incentivizes risk-taking and innovation in the face of long odds. Nine in ten drugs fail once they reach clinical trials. The possibility of a big payoff — or at least, enough revenue to cover development costs — is what keeps money flowing into pharmaceutical research.
If pharmaceutical firms can't expect to be paid prices commensurate with the value they'd command on the open market — as the federal government has made clear will be the case — then they're not going to attract the kind of investment needed to develop the next breakthrough cancer medicine or Alzheimer's therapy.
대한민국 최근 뉴스, 대한민국 헤드 라인
Similar News:다른 뉴스 소스에서 수집한 이와 유사한 뉴스 기사를 읽을 수도 있습니다.
Some Physicians Receive Thousands Of Dollars A Year From Drug Companies; Should You Be Concerned?How to know if your physician has a potential conflict of interest in their recommendations of medications or medical devices.
더 많은 것을 읽으십시오 »
| The Kremlin’s Latest Battle Is With Russia’s Oil CompaniesRosneft executives have been pushed out as the Kremlin and the country’s oil companies squabble over profits versus stability in the domestic energy market.
더 많은 것을 읽으십시오 »
China’s Business Environment Is Deteriorating, U.S. Companies SayMore than one-third of companies surveyed say they have reduced or paused Chinese investment in the past year.
더 많은 것을 읽으십시오 »
Tech companies try to take AI image generators mainstream with better protections against misuseArtificial intelligence tools that can conjure whimsical artwork or realistic-looking images from written commands started wowing the public last year. But most people don't actually use them at work or home.
더 많은 것을 읽으십시오 »